Millions of people in England could become eligible for NHS weight-loss jab injections as health officials widen the use of treatments aimed at tackling obesity and reducing the risk of heart attacks and strokes.
Read more breaking stories from our latest health news
The National Institute for Health and Care Excellence has recommended tirzepatide, sold as Mounjaro, for adults with obesity who also have weight-related health conditions. NICE estimates that about 3.4 million people in England fall within the wider eligible group, but access will be phased because the NHS cannot treat everyone immediately.
The treatment is expected to reach about 220,000 patients in the first three years. That means many people who meet the criteria may still have to wait while the NHS builds capacity, trains staff and puts the right monitoring systems in place.
Read related news:
Regulator warns on weight-loss jab scams
UK seizes £250,000 fake weight-loss drugs in factory raid
Pharmacists warn weight loss drug demand may outpace supply
Mounjaro is taken as a once-weekly injection. It helps people feel fuller for longer and reduces hunger, but it is not meant to work on its own. Patients are expected to use it alongside a reduced-calorie diet, regular physical activity and support from healthcare professionals.
For people who have lived for years with obesity, type 2 diabetes, high blood pressure, sleep apnoea or heart disease, the rollout could offer a new chance to improve their health. But it also exposes a difficult problem: demand for these medicines is far greater than the number of patients who can be treated quickly.
NICE has also expanded the role of semaglutide, sold as Wegovy, for some adults with established cardiovascular disease. The recommendation covers people with a BMI of at least 27 who have previously had a heart attack, stroke or serious circulation problem in the legs, known as peripheral arterial disease.
Unlike Mounjaro’s main rollout for obesity and weight-related conditions, this Wegovy recommendation is focused on reducing the risk of major cardiovascular events, including heart attacks and strokes. NHS England said around 1.2 million people with cardiovascular disease could become eligible for Wegovy over the next few years.
The expansion marks a major shift in how the NHS treats obesity and related illness. For years, many patients have been told to lose weight through diet and exercise alone, even when other health problems made that difficult. These medicines do not remove the need for lifestyle changes, but they give doctors another option for patients at higher clinical risk.
The phased rollout also shows how carefully the NHS is trying to manage access. These injections require assessment, follow-up and wider support. Patients may need help from doctors, nurses, dietitians, psychologists and specialist weight management teams. Without that support, the treatment may be less effective and safety concerns could be missed.
Health officials have warned that the medicines are not suitable for everyone. Possible side effects include nausea, vomiting, diarrhoea, constipation and other stomach problems. NHS England also says tirzepatide is not recommended for people who are pregnant, planning to become pregnant or breastfeeding. People taking the contraceptive pill are advised to use an additional method, such as a condom, because the medicine may affect absorption. Those using hormone replacement therapy are also advised to speak to their doctor about patches or gels.
There is growing interest in whether weight-loss injections could also help reduce sickness absence and improve productivity. A recent UK study reported that people using GLP-1 medicines had fewer sick days and made fewer GP visits, adding to debate over whether the drugs could support people back into work and ease pressure on public services.
Still, doctors and health leaders say the jabs should not be seen as a simple shortcut. Obesity is a long-term health condition affected by biology, income, food environment, mental health, work patterns and access to care. A weekly injection may help many patients, but it cannot replace safe prescribing, regular monitoring and wider public health support.
For patients, the message is hopeful but realistic. Mounjaro and Wegovy could help people who face serious health risks linked to weight, but not everyone who qualifies will get access straight away. Some will be treated through specialist services. Others may wait as the NHS expands capacity.
The rollout is a breakthrough for obesity and heart disease treatment in England. The real test will be whether the NHS can deliver it fairly, safely and quickly enough for the millions who may benefit.
